There is one clinical trial.
The aim of this study is to test whether Traditional Chinese Medicines (TCMs) are effective and safe for treating COVID-19 infection. After the enrolment of approximately 30 subjects, the recruitment will be paused, and planned interim analysis will be performed to preliminarily investigate the efficacy and safety of TCMs in patients infected with COVID-19.
Description: The incidence rate of acute respiratory distress syndrome (ARDS) development
Measure: The incidents of acute respiratory distress syndrome (ARDS) development Time: 14 daysDescription: Time to complete remission of fever in eligible subjects
Measure: The time to fever resolution rate Time: 14 daysDescription: improvement of chest radiographic evidence indirectly reflects recovery in patients infected with COVID-19.
Measure: Time to recovery of lung injury Time: 14 daysDescription: The rate of subject who die will be described.
Measure: Rate of subjects who die Time: 28 daysDescription: The rate of subjects with severe 2019-nCoV infection who receive systematic corticosteroids will be described.
Measure: Rate of subjects receiving systematic corticosteroids Time: 28 daysDescription: The length of hospital stays
Measure: The length of hospital stays Time: 28 daysDescription: The duration of respiratory support including invasive and non-invasive mechanical ventilation
Measure: The duration of respiratory support Time: 28 days